Hassman Research Institute – A New Option for Your Renal and Hepatic Impairment Studies
With 20+ years of research experience, Hassman Research Institute
(HRI) understands patients’ needs and trial designs, and has the state-of-the-art facility to successfully execute your next trial. HRI’s track record on hep C and hepatic and renal impairment trials is excellent, with an over 100% enrollment and completion rate to goal.
HRI is a full-time dedicated research organization consisting of 3 units on a large campus in Berlin, New Jersey. The inpatient facility was built with flexible space to accommodate rigorous assessments and special patient populations, with 30 beds, an on-site pharmacy, and local stat lab.
HRI has a database of over 70,000 subjects and access to patients via 5 multi-specialty affiliated practices. HRI employs a full-time research staff including dedicated recruiters and an independent quality assurance department.
Contact us to set up a tour, arrange an in-person or introductory call with Chief Scientific Officer Dr. Howard Hassman and principals, or request more information. May we provide protocol feedback, feasibility information, and/or a draft budget for your review?
Recent renal and hepatic metrics:
‣ Enrolled and completed 16 subjects with severe renal impairment and subjects with normal renal function in 4 months in a phase I study comparing the pharmacokinetics of study drug.
‣ Enrolled and completed 24 subjects with hepatic impairment and age, weight/BMI and gender-matched controls in 5 months in a phase I systemic pharmacokinetics single dose, open-label study of the plasma and urinary pharmacokinetics of study drug and its major metabolites.